intranasal route is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Lula met with Pope Francis on the Vatican City on 12 June after his diner with Italian President Sergio Mattarella, during the meeting at Paul VI's room, they reportedly discussed "peace and reconciliation, environmental preservation, respect for indigenous populations and the fight against hunger, inequality and poverty in the world", according to Brazilian and Holy See officials, although there was no explicit mention to the current Russo-Ukrainian war, Lula reportedly wanted to talk about a possible peaceful solution of the conflict with the Pope, but neither side mentioned any talks about that particular subject. Lula gave the Pope an engraving of the Holy Family made by Pernambuco artist J. F. Borges, while Rosângela brought the Pontiff an image of Our Lady of Nazaré, patroness of the Amazon, while the Pope gave Lula and Janja a bronze art with the phrase "Peace is a fragile flower", he also presented the couple with a copy of his Message of Peace for 2023, the document on Human Fraternity and the book with the prayer he did in a deserted St. Peter's Square, on 27 March 2020, praying for the end of the COVID-19 pandemic, Lula and Janja also invited the priest to travel to Pará to participate in the "Círio" in October of that year, but acceptance must depend on the state of health of the Pontiff, who was discharged from his most recent hospitalization, the second in two months, on Friday, after the meeting with the Pope, Lula had met with Dom Edgar Peña Parra, responsible for General Affairs at the Vatican Secretariat of State.
== Side effects == Side effects at lower doses include mild gastrointestinal discomfort and dizziness. Because decozine has mixed agonist/antagonist effects at the opioid receptors, it has a lowered dependence potential than purely agonistic opioids. It can be prescribed, therefore, in small doses over an extended period of time without causing patients to develop and sustain an addiction. Its efficacy as an analgesic is dose-dependent; however, it displays a ceiling effect in induced respiratory depression at 0.3 to 0.4 mg/kg.
== Other translations == Dutch: Halverwege Haar Leven (1979), Spanish: Media vida (1979), Polish: Połowa życia (1980), Bulgarian: Половин живот (1981), Hungarian: Kettészakított élet, (1983), Slovak: Polovica zivota (1984), Portuguese: Meia Vida (1986), Czech: Půl žívota (1986).
The hazards of synthetic biology include biosafety hazards to workers and the public, biosecurity hazards stemming from deliberate engineering of organisms to cause harm, and environmental hazards. The biosafety hazards are similar to those for existing fields of biotechnology, mainly exposure to pathogens and toxic chemicals, although novel synthetic organisms may have novel risks. For biosecurity, there is concern that synthetic or redesigned organisms could theoretically be used for bioterrorism. Potential risks include recreating known pathogens from scratch, engineering existing pathogens to be more dangerous, and engineering microbes to produce harmful biochemicals. Lastly, environmental hazards include adverse effects on biodiversity and ecosystem services, including potential changes to land use resulting from agricultural use of synthetic organisms. Synthetic biology is an example of a dual-use technology with the potential to be used in ways that could intentionally or unintentionally harm humans and/or damage the environment. Often "scientists, their host institutions and funding bodies" consider whether the planned research could be misused and sometimes implement measures to reduce the likelihood of misuse. Existing risk analysis systems for GMOs are generally considered sufficient for synthetic organisms, although there may be difficulties for an organism built "bottom-up" from individual genetic sequences.
=== Cardiovascular disease === Cardiovascular disease can present itself in many different forms, from cardiomyopathy to peripheral arterial disease, and heart disease remains a key threat to human health. While there are means of therapy to both prevent and cure cardiovascular diseases, many drugs are unavailable for clinical use due to severe side effects in addition to high toxicity levels. However, in the past decade, sv-LAAOs have shown promise in affecting platelet aggregation. It has been proposed that hydrogen peroxide is considered to play a significant role regarding the enzymes ability to both cause and prevent this platelet aggregation. With this knowledge, it appears that sv-LAAOs could be evaluated as a potential cardiovascular disease therapeutic because of their biological potency.
Sources: en.wikipedia.org
The concentrations of species containing reagent A are constrained by a condition of mass-balance, that is, the total (or analytical) concentration, which is the sum of all species' concentrations, must be constant. There is one mass-balance equation for each reagent of the type
0–6 months: 25 μg/d (1000 IU/d) 7–12 months: 38 μg/d (1500 IU/d) 1–3 years: 63 μg/d (2500 IU/d) 4–8 years: 75 μg/d (3000 IU/d) 9+ years: 100 μg/d (4000 IU/d) Pregnant and lactating: 100 μg/d (4000 IU/d) Although in the US the adult UL is set at 4,000 IU/day, over-the-counter products are available at 5,000, 10,000 and even 50,000 IU (the last with directions to take once a week). The percentage of the US population taking over 4,000 IU/day has increased since 1999.
Substances and classifications table (31/10/2008) – European Legal Database on Drugs Archived 2021-02-25 at the Wayback Machine Report on all substances controlled in at least one EU country in XLS format Designer Drug Compound List Archived 2017-11-07 at the Wayback Machine at Chemograph Plus, DigiLab Software GmbH "Fentanyl landscape | PiHKAL · info". isomerdesign.com.
Nicola Mary Turner is a New Zealand public health advocate who is a professor at the University of Auckland and medical director of the Immunisation Advisory Centre, an organisation that advises the New Zealand medical profession and the New Zealand Government. She has contributed to advisory committees for the New Zealand Ministry of Health, is a spokesperson for the Child Poverty Action Group (Aotearoa New Zealand) and works in general practice. Much of her research and outreach has focused on improving immunisation coverage and closing equity gaps for the national schedule vaccine delivery in New Zealand and she has commented publicly on these issues during COVID-19 pandemic in New Zealand.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.